Serey C.L. Nouth

Serey C.L. Nouth

Auto-generated profile, based on publicly available information

Serey C.L. Nouth

Department of Radiation Oncology, Stanford University, Stanford, CA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2025 in Cancer Research
Verified
Journal Article
Closed access
EBErik S. Blomain
Erik S. Blomain
SSShaghayegh Soudi
Shaghayegh Soudi
ZWZiwei Wang
Ziwei Wang
ASAnish Somani
Anish Somani
ASAjay Subramanian
Ajay Subramanian
EMEverett J. Moding
Everett J. Moding
Radiotherapy is an integral component in the treatment of many types of cancer, with approximately half of patients with cancer receiving radiotherapy. Systemic therapy applies pressure that can select for resistant tumor subpopulations, underscoring the importance of understanding how radiation impacts tumor evolution to improve treatment outcomes. We integrated temporal genomic profiling of 120 spatially distinct tumor regions from 20 patients with undifferentiated pleomorphic sarcomas (UPS), longitudinal circulating tumor DNA analysis, and evolutionary biology computational pipelines to study UPS evolution during tumorigenesis and in response to radiotherapy. Most unirradiated UPSs displayed initial linear evolution, followed by subsequent branching evolution with distinct mutational processes during early and late development. Metrics of genetic divergence between regions provided evidence of strong selection pressures during UPS development that further increased during radiotherapy. Subclone abundance changed after radiotherapy with subclone contraction tied to alterations in calcium signaling, and inhibiting calcium transporters radiosensitized sarcoma cells. Finally, circulating tumor DNA analysis accurately measured subclone abundance and enabled noninvasive monitoring of subclonal changes. These results demonstrate that radiation exerts selective pressures on UPSs and suggest that targeting radioresistant subclonal populations could improve outcomes after radiotherapy. Significance: Radiotherapy mediates tumor evolution by leading to the expansion of resistant subclonal cancer cell populations, indicating that developing approaches to target resistant subclones will be crucial to improve radiotherapy response.

20 October 2026 in Journal of Clinical Oncology
Verified
Journal Article
Open access
ASAjay Subramanian
Ajay Subramanian
SNSerey C.L. Nouth
Serey C.L. Nouth
NNNeda Nemat-Gorgani
Neda Nemat-Gorgani
SSShaghayegh Soudi
Shaghayegh Soudi
KBKarla V. Ballman
Karla V. Ballman
EMEverett J. Moding
Everett J. Moding
PURPOSE: Circulating tumor DNA (ctDNA) holds promise for prognostication and disease monitoring in solid tumors. However, rare and heterogenous tumors with low mutational burden like soft tissue sarcomas (STS) present a technical challenge for ctDNA analysis. We investigated the ability of personalized ctDNA analysis to predict outcomes and track response to radiotherapy and pembrolizumab in patients with localized STS. METHODS: We analyzed 313 plasma samples collected pretreatment, postradiotherapy/presurgery, and postsurgery from 106 patients treated with preoperative radiotherapy with or without perioperative pembrolizumab for high-risk, localized STS in the SU2C-SARC032 phase II randomized trial. Personalized ctDNA assays were designed to track a median of 46 somatic mutations per patient. Associations between ctDNA levels and outcomes were assessed using univariable and multivariable models adjusting for clinical risk factors. RESULTS: Personalized ctDNA profiling detected baseline ctDNA in 85% of patients. Baseline ctDNA levels correlated with tumor size, grade 3 disease, and expression of genes related to hypoxia and the cell cycle. ctDNA levels pretreatment, after radiotherapy with or without immunotherapy but before surgery, and postsurgery were strongly associated with disease-free and overall survival on univariable and multivariable analyses. Patients treated with pembrolizumab, who had significantly better disease-free survival, had a greater decrease in their ctDNA levels after neoadjuvant therapy. Finally, personalized ctDNA analysis enabled noninvasive subclone tracking and patients with multiple tumor clones detected by ctDNA analysis after surgery had inferior outcomes. CONCLUSION: Tumor-informed, personalized profiling enables sensitive ctDNA detection and quantitative monitoring in localized STS, providing independent prognostic information across the perioperative course. These findings support prospective ctDNA-guided interventional trials in STS.

17 June 2026
Verified
Other
Open access
EBErik S. Blomain
Erik S. Blomain
SSShaghayegh Soudi
Shaghayegh Soudi
ZWZiwei Wang
Ziwei Wang
ASAnish Somani
Anish Somani
ASAjay Subramanian
Ajay Subramanian
EMEverett J. Moding
Everett J. Moding
Supplementary Figures S1-S6 and Supplementary Methods

14 March 2025
Verified
Other
Open access
PDF file
EBErik S. Blomain
Erik S. Blomain
SSShaghayegh Soudi
Shaghayegh Soudi
ZWZiwei Wang
Ziwei Wang
ASAnish Somani
Anish Somani
ASAjay Subramanian
Ajay Subramanian
EMEverett J. Moding
Everett J. Moding
Supplementary Figures S1-S6 and Supplementary Methods

14 March 2025
Verified
Other
Open access
EBErik S. Blomain
Erik S. Blomain
SSShaghayegh Soudi
Shaghayegh Soudi
ZWZiwei Wang
Ziwei Wang
ASAnish Somani
Anish Somani
ASAjay Subramanian
Ajay Subramanian
EMEverett J. Moding
Everett J. Moding
Supplementary Tables from Evolutionary Pressures Shape Undifferentiated Pleomorphic Sarcoma Development and Radiotherapy Response

17 June 2026
Verified
Other
Open access
EBErik S. Blomain
Erik S. Blomain
SSShaghayegh Soudi
Shaghayegh Soudi
ZWZiwei Wang
Ziwei Wang
ASAnish Somani
Anish Somani
ASAjay Subramanian
Ajay Subramanian
EMEverett J. Moding
Everett J. Moding
Supplementary Tables from Evolutionary Pressures Shape Undifferentiated Pleomorphic Sarcoma Development and Radiotherapy Response